Retatrutide

What is Retatrutide?

Retatrutide, often referred to online as "reta" for short, is a new weight loss drug from Eli Lilly that is still under investigation. It is a weekly injection that simultaneously acts on three hormone receptors: GLP-1, GIP, and glucagon. Mounjaro works on two of these and Wegovy on one. The initial results from the large phase 3 studies are very promising. In the largest study, participants on the highest dose lost an average of 28.3% of their body weight after 80 weeks.

*Retatrutide is not yet approved anywhere in the world.

Buying Retatrutide

Because retatrutide is currently in the research phase, it cannot yet be purchased. It is expected that, like other weight loss medications, it will be a prescription-only drug, meaning it will only be available with a doctor's prescription. In the Netherlands, this is not expected before the end of 2027. If retatrutide is offered online now, it is always an illegal and uncontrolled product. Read more about the risks of illegally purchased weight loss medication. The Body Clinic does not sell or mediate retatrutide.

Retatrutide Price

No price is known yet. A price will only be set after a drug is approved, and it may vary per country. Please note: any price you see online now always belongs to an illegal product.

Compare medications

Products:	Retatrutide
Pharmacist:	Eli Lilly
Active ingredient:	Retatrutide
Treatment type:	Obesity and type 2 diabetes
Dosage:	-
Administration:	Once a week
Approval phase:	Research phase
Side effects:	No overview of possible side effects known yet

Who is Retatrutide Peptide suitable for?

The studies included adults with a BMI (Body Mass Index) of: 30 or higher (obesity) or 27 to 30 (overweight) with at least one weight-related condition, such as type 2 diabetes, high blood pressure, high cholesterol, osteoarthritis, or sleep apnea. The target demographic for retatrutide will be determined once the medication is approved.

Retatrutide Prescription

Retatrutide is only available by prescription from a doctor if the patient meets the indications described above. However, the research phase still needs to be completed, and it is currently unclear if and when it will enter the Dutch market.

How Retatrutide Works

Retatrutide acts on three hormone receptors simultaneously: GLP-1, GIP, and glucagon. Together, they help reduce appetite, promote a feeling of fullness more quickly, regulate blood sugar, and stimulate fat burning.

Is Retatrutide Safe?

Retatrutide has not yet been approved by the FDA and the Ministry of Public Health. The drug is still in the research phase and therefore cannot yet receive approval.

The difference between Retatrutide and Tirzepatide

Tirzepatide has a dual mechanism of action, while retatrutide has a triple mechanism of action.

Person self-injecting insulin into their abdomen with a medical pen.

Switching to Retatrutide: is it possible yet?

No. As long as retatrutide has not been approved, no one can switch you to it, not even if you are already using Wegovy or Mounjaro. Therefore, do not stop your current medication: those who stop a GLP-1 agent often regain a large part of the lost weight. Also, do not switch via a webshop, because you don't know what you are injecting there. How a safe transition will proceed will only become clear after approval. You will then make that decision together with your treating physician.

Retatrutide Reimbursement by the Health Insurer

The drug retatrutide has not yet been approved by the FDA and the Ministry of Public Health. Therefore, it is not yet possible to say whether it will be reimbursed in the future.

Retatrutide Dosage

In the phase 3 studies, participants received 4, 9, or 12 mg once a week. The dose was built up step by step. Which dosages will become available depends on the approval.

Where to Inject Retatrutide?

Retatrutide is administered via a subcutaneous injection. Do not inject it into a vein or muscle. The best places to inject are:

in the thigh
in the lower abdomen
in the upper arm

Frequently asked questions about retatrutide

Reta is the abbreviation many people use online for retatrutide, Eli Lilly's experimental weight-loss drug. It is not yet approved and not legally available.
In the largest study, participants on the highest dose lost an average of 28.3% of their body weight after 80 weeks. For people with type 2 diabetes, this was less, up to 20.8%.
During the 3-phase study, mainly gastrointestinal complaints such as nausea, diarrhea, and constipation occurred. Additionally, skin tingling (dysesthesia) and slightly more frequent urinary tract infections were reported. Most complaints were mild to moderate.
Not yet. Lilly plans to submit the application in the US in the first quarter of 2027, with Europe following afterwards. Retatrutide is not expected to be available in the Netherlands before the end of 2027.
Not yet, as retatrutide has not been approved by the FDA and the Ministry of Health. Do not stop your current medication and discuss a potential switch with your doctor after approval.